Last update July 30, 2022

Celiprolol Hydrochloride

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is a cardioselective β1-adrenergic blocker used in the treatment of hypertension and angina pectoris. Oral administration once daily.

Since the last update we have not found published data on its excretion in breastmilk.

Its low percentage of plasma protein binding make it likely that it would pass into breast milk in amounts which could be significant (Riant 1986), although its very wide volume of distribution would make it difficult.

Its low oral bioavailability (even more decreased with food) makes it difficult for it to pass to the infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability.

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Celiprolol Hydrochloride in other languages or writings:

Groups

Celiprolol Hydrochloride belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Celiprolol Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 55 %
Molecular weight 416 daltons
Protein Binding 25 - 30 %
VD 4.5 l/Kg
pKa 13.55 -
Tmax 1 -3 hours
5 (4 - 6) hours

References

  1. Sanofi-A. Celiprolol. Drug Summary. 2018 Full text (in our servers)
  2. Tamargo Menéndez J, Delpón Mosquera E. Farmacología de los bloqueantes de los receptores β-adrenérgicos. Curso βeta 2011 de Actualización en Betabloqueantes. 2011 Full text (in our servers)
  3. Riant P, Urien S, Albengres E, Duche JC, Tillement JP. High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochem Pharmacol. 1986 Abstract

Total visits

2,997

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM